Eone Diagnomics Genome Center Valuation
Is A245620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of A245620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von A245620 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von A245620 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A245620?
Other financial metrics that can be useful for relative valuation.
What is A245620's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩57.39b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.6x |
Enterprise Value/EBITDA | -50.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A245620's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.4x | ||
A187660 ADM Korea | 4.9x | n/a | ₩67.7b |
A036180 GW VitekLTD | 1.3x | n/a | ₩60.6b |
A114450 Green Lifescience | 1.9x | n/a | ₩43.5b |
A359090 C&R Research | 1.4x | n/a | ₩79.2b |
A245620 Eone Diagnomics Genome Center | 0.6x | n/a | ₩57.4b |
Price-To-Sales gegen Gleichaltrige: A245620 ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (0.5x) mit dem Durchschnitt der anderen Unternehmen (2x) vergleicht.
Price to Earnings Ratio vs Industry
How does A245620's PE Ratio compare vs other companies in the KR Life Sciences Industry?
Price-To-Sales gegen Industrie: A245620 ist aufgrund seines Price-To-Sales Verhältnisses (0.5x) im Vergleich zum KR Life Sciences Branchendurchschnitt (4.2x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is A245620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von A245620 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.